For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A Randomized, Phase II/III Study Of Pegylated Liposomal Doxorubicin And Ctep-Supplied Atezolizumab (Ind #134427) Versus Pegylated Liposomal Doxorubicin/Bevacizumab And Ctep-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab In Platinum Resistant Ovarian Cancer
To compare any good and bad effects of adding Atezolizumab to the usual chemotherapy, (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab.
DiagnosisHigh grade ovarian cancer, including high grade serous; clear cell; endometroid, grade 3, and others (adenocarcinoma, NOS, mixed epithelial carcinoma; undifferentiated carcinoma).
Must have had at least one prior platinum based therapy
Must have cancer recurrence or progression within < 6 months from completion of platinum based therapy. The date will be calculated from the last administered dose.
Measurable or evaluable disease
Adequate kidney, liver and thyroid function
Negative pregnancy test if of child bearing potential
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Study agents:Peglyated liposomal Doxorubicin, Atezolizumab, Bevacizumab
- Quality of Life questionnaires
- ARM A: Liposomal doxorubicin and Atezolizumab. (Study Group)
- ARM B: Liposomal doxorubicin and Atezolizumab and Bevacizumab (Study Group)
- ARM C: Liposomal doxorubicin and Bevacizumab (Usual approach)
- Follow ups occur every 3 months for 2 years and then every 6 months for 3 years.
For more information, visit ClinicalTrials.gov